Monoamine oxidase and cigarette smoking

NeuroToxicology

Volumn 24, Issue 1, 2003, Pages 75-82

  Fowler, Joanna S ^a   Logan, Jean ^a   Wang, Gene Jack ^a   Volkow, Nora D ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Cigarette smoking; Monoamine oxidase; Positron emission tomography; Smoking cessation; Smoking epidemiology; Tobacco

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); TOBACCO SMOKE;

ARTICLE; CIGARETTE SMOKING; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME MECHANISM; EPIDEMIOLOGICAL DATA; HUMAN; MENTAL DISEASE; NONHUMAN; PASSIVE SMOKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMOKING CESSATION; THROMBOCYTE; TOBACCO;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; SMOKING; SMOKING CESSATION;

ANIMALIA; GYMNOMYZA SAMOENSIS; NICOTIANA TABACUM;

EID: 0037231224     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00109-2     Document Type: Article

References (74)

1. Anthenelli RM, Tipp J, Li T-K, Magnes L, Schuckit MA, Rice J, et al. Platelet monoamine oxidase activity in subgroups of alcoholics and controls: results from the Collaborative Study on the Genetics of Alcoholism. Alcohol Clin Exp Res 1998; 22:598-604.
2. Bach AWJ, Lan NC, Johnson DL. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988;85: 4934-8.
3. Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, et al. Measurement of human cerebral monoamine oxidase type B (MAO B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991;40:169-73.
4. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. New Engl J Med 1988;319:1318-29.
5. Berlin I, Anthenelli RM. Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol 2001;4:33-42.
6. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry 1995a;38:756-61.
7. Berlin I, Said S, Spreux Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995;58(4): 444-52.
8. Berlin I, Spreux-Varoquaux O, Said S, Launay JM. Effects of past history of major depression on smoking characteristics. Drug Alcohol Depend 1997;45:31-7.
9. Berlin I, Spreux-Varoquaux O, Launay JM. Platelet monoamine oxidase B activity is inversely associated with plasma cotinine concentration. Nicotine Tob Res 2000;2:243-6.
10. Blaschko H, Richter D, Schlossmann H. The inactivation of adrenaline. J Physiol Lond 1937;90:1-17.
11. Brauer LH, Paxton DA, Rose JE. Selegiline and transdermal nicotine for smoking cessation. In: Proceedings of the Sixth Annual Meeting of the Society for Research on Nicotine and Tobacco, Feb 18-20, Arlington, VA. 2000.
12. Buchsbaum MS, Coursey RD, Murphy DL. The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science 1976;194: 339-41.
13. Carr LA, Basham JK. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci 1991;48:1173-7.
14. Carr LA, Rowell PP. Attenuation of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacology 1990;29:311-4.
15. Castagnoli KP, Steyn SJ, Petzer JP, Van der Schyf CJ, Castagnoli Jr, N. Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chem Res Toxicol 2001;14:523-7.
16. Cohen G, Farooqui R, Kesler N. Parkinson's disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 1997;94:4890-4.
17. Coursey RD, Buchsbaum MS, Murphy DL. Platelet MAO activity and evoked potentials in the identification of subjects biologically at risk for psychiatric disorders. Br J Psychiatry 1979; 134:372-81.
18. Crane GE. Psychiatric side effects of iproniazide. Am J Psychiatry 1956;112:494-7.
19. Devor EJ, Cloninger CR, Hoffman PL, Tabakoff B. Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. Am J Hum Genet 1993;48:209-13.
20. Essman WB. Serotonin and monoamine oxidase in mouse skin: effects of cigarette smoke exposure. J Med 1977;8:95-101.
21. Farren CK, Clare AW, Tipton KF, Dinan TG. Platelet MAO activity in subtypes of alcoholics and controls in a homogenous population. J Psychiatry Res 1998;32:49-54.
22. 11C-suicide inactivators and positron emission tomography. Science 1987;235:481-5.
23. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schlyer D, et al. Slow recovery of human brain MAO B after L-deprenyl withdrawal. Synapse 1994;18:86-93.
24. 11C]L-deprenyl-D2 for MAO B mapping. J Nucl Med 1995;36:1255-62.
25. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, Shea C, et al. Brain MAO A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996a;93:14065-9.
26. Fowler JS, Wang G-J, Volkow ND, Pappas N, Logan J, MacGregor RR, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996b;379:733-6.
27. Fowler JS, Volkow ND, Logan J, Pappas N, King P, MacGregor R, et al. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci 1998;63(2):PL19-23.
28. Fowler JS, Wang G-J, Volkow ND, Franceschi D, Logan J, Pappas N, et al. Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. Nicotine Tob Res 1999;1:325-9.
29. Fowler JS, Wang G-J, Volkow ND, Franceschi D, Logan J, Pappas N, Shea CS, et al. Maintenance of brain monoamine oxidase B inhibition in smokers after an overnight cigarette abstinence. Am J Psychiatry 2000;157:1864-6.
30. Garpenstrand H, Longato-Stadler E, af Klinteberg B, Grigorenko E, Damberg M, Oreland L, et al. Low platelet monoamine oxidase activity in Swedish imprisoned criminal offenders. Eur Neuropsychopharmacol 2002;12:135-40.
31. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. J Am Med Assoc 1990;264:1546-9.
32. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001;357:1929-32.
33. Hare MLC. Tyramine oxidase. I. A new enzyme system in liver. Biochem J 1928;22:968-79.
34. Hauptmann N, Shih JC. 2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci 2001;68:1231-41.
35. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-74.
36. Hellenbrand W, Seidler A, Robra B-P, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson's disease: a case-control study in Germany. Int J Epidemiol 1997;26:328-39.
37. Henningfield JE, Clayton R, Pollen W. Involvement of tobacco in alcoholism and illicit drug use. Br J Addict 1990;85:279-82.
38. Hernan MA, Checkoway H, O'Brien R, Costa-Mallen P, De Vivo I, Colditz GA, et al. MAO B intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk. Neurology 2002;58:1381-7.
39. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7.
40. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
41. Jossan SS, Sakurai E, Oreland L. Is monoamine oxidase B activity rate limiting for MPTP neurotoxicity? Biogenic Amines 1987;4:371-9.
42. Khalil AA, Steyn S, Castagnoli N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 2000;13:31-5.
43. Knoll J, Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408.
44. Langston JW, Ballard JW, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-80.
45. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced Parkinsonism in primates. Science 1984;225: 1480-3.
46. McDaniel K. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986;9:207-34.
47. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiological clue? Neurology 1995;45:1041-51.
48. Norman TR, Chamberlain KD, French MA, Burrows GD. Platelet monoamine oxidase activity and cigarette smoking. J Affect Disord 1982;4:73-7.
49. Norman TR, Chamberlain KG, French MA. Platelet monoamine oxidase: low activity in cigarette smokers. Psychiatry Res 1987;20:199-205.
50. Oreland L, Fowler CJ, Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 1981;29:2511-8.
51. Oreland L, Garpenstrand H, Damberg M, Alm PO, Thorell LH, af Klinteberg B, et al. The correlation between platelet MAO activity and personality - the effect of smoking and possible mechanisms behind the correlation. Neurobiology (Bp) 1999; 7:191-203.
52. Pavlin R, Sket D. Effect of cigarette smoke on brain monoamine oxidase activity, Farmacevtski Vestnik 1993;44:185-92.
53. Richards JG, Saura J, Luque JM, Cesura AM, Gottowik J, Malherbe P, et al. Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. J Neural Transm Suppl 1998;52:173-87.
54. Rose JE, Behm FM, Ramsey C, Ritchie Jr, JC. Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 2001;3:383-90.
55. Ryan RE, Ross SA, Drago J, Loiacono RE. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol 2001;132: 1650-6.
56. Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvalahti E, Hietala J. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 2000;157:632-4.
57. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-22.
58. Selikoff I, Robitzek E, Ornstein G. Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. J Am Med Assoc 1952;150:973-80.
59. Sellers EM. Pharmacogenetics and ethnoracial differences in smoking. J Am Med Assoc 1998;280:179-80.
60. Shahi GS, Das NP, Moochhala SM. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by beta-naphthoflavone-pretreatment. Neurosci Lett 1991;127:247-50.
61. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Ann Rev Neurosci 1999;22:197-217.
62. Simpson GM, Shih JC, Chen K, Flowers C, Kumazawa T, Spring B. Schizophrenia, monoamine oxidase activity, and cigarette smoking. Neuropsychopharmacology 1999;20:392-4.
63. Singer T. Monoamine oxidases: old friends hold many surprises. FASEB J 1995;9:605-10.
64. Soto-Otero R, Mendez-Alvarez E, Riguera-Vega R, Quinoa-Cabana E, Tabakoff B, Hoffman PL, et al. Differences in platelet enzyme activity between alcoholics and nonalcoholics. N Engl J Med 1988;318:134-9.
65. Soto-Otero R, Mendez-Alvarez E, Riguera-Vega R, Quinoa-Cabana E, Sanchez-Sellero I, Lopez-Rivadulla, Lamas M. Studies on the interaction between 1,2,3,4-tetrahydro-beta-carboline and cigarette smoke: a potential mechanism of neuroprotection for Parkinson's disease. Brain Res 802;1998:155-62.
66. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-22.
67. Vindis C, Seguelas MH, Lanier S, Parini A, Cambon C. Dopamine induces ERK activation in renal tubule epithelial cells through H202 produced by monoamine oxidase. Kidney Int 2001;59: 76-86.
68. von Knorring L, Oreland L. Personality traits and platelet monoamine oxidase in tobacco smokers. Psychol Med 1985;15:327-34.
69. Wiberg A, Gottfries CG, Oreland L. Low platelet monoamine oxidase activity in human alcoholics. Med Biol 1977;55:181-6.
70. Yong VW, Perry TL. Monoamine oxidase B. J Neurol Sci 1986; 72:265-72.
71. Youdim MDH, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm 1993;91:181-95.
72. Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987;41:675-82.
73. Zeller EA, Barsky J, R E. Amine oxidases. XI. Inhibition of monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. J Biol Chem 1955;214:267-74.
74. Zeller EA. Uber den enzymatischen abbau von histamin und diaminen. Helv Chim Acta 1938;21:880-90.